Evidence map›Paper›PMID 37806461›Full record

ReviewGastroenterology2024

Evolving Concepts in Helicobacter pylori Management.

Steven F Moss, Shailja C Shah, Mimi C Tan, Hashem B El-Serag

Open access · bronzeAbstract readReview
In one paragraph

Review in Gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 2 pooled it
29.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.

  1. Gastric cancer prevention byFrontiers in oncology · 2026
    Pooled it
  2. Guideline
  3. Trial
  4. Efficacy and safety of triple therapy with vonoprazan forWorld journal of gastroenterology · 2025
    Trial
  5. Article
  6. Review
  7. Association of Resistance-AssociatedAntibiotics (Basel, Switzerland) · 2026
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. The Effects ofJournal of clinical medicine · 2026
    Review
  15. Review
  16. Barriers toBMJ open · 2026
    Article
  17. OptimizingWorld journal of gastroenterology · 2026
    Article
  18. Article
  19. Targeting ferroptosis inInternational journal of oncology · 2026
    Review
  20. Advances in the Management of RefractoryGastro hep advances · 2026
    Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Steven F MossBrown University, Providence, Rhode Island; Providence VA Medical Center, Providence, Rhode Island.
Shailja C ShahUniversity of California at San Diego, San Diego, California; VA San Diego Healthcare System, San Diego, California.
Mimi C TanSection of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas.
Hashem B El-SeragSection of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas. Electronic address: hasheme@bcm.edu.
Baylor College of Medicine · USBrown University · USUniversity of California San Diego · US

Funding

Tissue Analysis & Molecular Imaging CoreP30DK056338 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI Hashem B El-Serag · 2001 to 2026
$28.3M
San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2019 to 2026
$10.8M
Development and Validation of an Automated Algorithm for Real-time Detection of Neoplasia in Barrett's Esophagus using a Low-cost, Portable MicroendoscopeK23DK129776 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI Mimi Chang Tan · 2022 to 2026
$993k
Optimization of Helicobacter pylori-related Disease Outcomes in VeteransIK2CX002027 · VA · VETERANS HEALTH ADMINISTRATION · PI SHAILJA C SHAH · 2020 to 2026
–
CSRD VA IK2 CX002027NIDDK NIH HHS K23 DK129776NIDDK NIH HHS P30 DK056338NIDDK NIH HHS P30 DK120515
6 · The paper itself

Abstract

Helicobacter pylori is the most common chronic bacterial infection worldwide and the most significant risk factor for gastric cancer, which remains a leading cause of cancer-related death globally. H pylori and gastric cancer continue to disproportionately impact racial and ethnic minority and immigrant groups in the United States. The approach to H pylori case-finding thus far has relied on opportunistic testing based on symptoms or high-risk indicators, such as racial or ethnic background and family history. However, this approach misses a substantial proportion of individuals infected with H pylori who remain at risk for gastric cancer because most infections remain clinically silent. Moreover, individuals with chronic H pylori infection are at risk for gastric preneoplastic lesions, which are also asymptomatic and only reliably diagnosed using endoscopy and biopsy. Thus, to make a significant impact in gastric cancer prevention, a systematic approach is needed to better identify individuals at highest risk of both H pylori infection and its complications, including gastric preneoplasia and cancer. The approach to H pylori eradication must also be optimized given sharply decreasing rates of successful eradication with commonly used therapies and increasing antimicrobial resistance. With growing acceptance that H pylori should be managed as an infectious disease and the increasing availability of susceptibility testing, we now have the momentum to abandon empirical therapies demonstrated to have inadequate eradication rates. Molecular-based susceptibility profiling facilitates selection of a personalized eradication regimen without necessitating an invasive procedure. An improved approach to H pylori eradication coupled with population-level programs for screening and treatment could be an effective and efficient strategy to prevent gastric cancer, especially in minority and potentially marginalized populations that bear the heaviest burden of H pylori infection and its complications.

Indexed as

Helicobacter InfectionsHelicobacter pyloriStomach NeoplasmsAnti-Bacterial AgentsEthnicityHumansMinority GroupsRisk FactorsAnti-Bacterial AgentsAntibiotic ResistanceGastric CancerGastric Cancer ScreeningGastric Intestinal MetaplasiaHelicobacter pyloriH pylori TreatmentSusceptibility TestingUnder-represented Minorities

Identifiers

PMID37806461
PMCPMC10843279
OpenAlexW4387404223

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.